Tisagenlecleucel,Axicabtagene ciloleucel,fludarabine,cyclophosphamide
Novartis ,gilead,daiichi sankyo
['bet', 'dlbcl', 'lysa', 'fludarabine', 'equate', 'axi-cel', 'cyclophosphamide', 'nhl', 'lymsm', 'aura ,(-laura)']
axi-cel as second line therapy for lbcl in transplant ineligible pts (lysa trial): 70% of pts meet endpoint of cmr at 3 months #ash22 #lymsm 
Hem/Onc fellow @WeillCornell | #bmtsm #Celltherapy I share my tweets in @HematologyTweet